Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.

Beste LA, Green PK, Berry K et al.

General Medicine Service, Veterans Affairs Puget Sound Health Care System; Health Services Research and Development, Veterans Affairs Puget Sound Health Care System; General Internal Medicine, University of Washington. Electronic address: lauren.beste@va.gov.

Journal of hepatology. Mar 2017.

Hepatitis C virus (HCV) treatment for patients with hepatocellular carcinoma (HCC) was uncommon before direct acting antiviral (DAA) medications. Real-world effectiveness of DAAs for HCV in patients with HCC is unclear. We describe rates of sustained virologic response (SVR) with DAA regimens by HCV genotype in patients with history of HCC.We identified patients who initiated antiviral treatment between January 1, 2014 and June 30, 2015 in the national Veterans Affairs health care system. Regimens included sofosobuvir, ledipasvir/ sofosbuvir, and paritaprevir/ ritonavir/ ombitasvir and dasabuvir with or without ribavirin. HCC patients were divided into those who were treated with liver transplantation after HCC diagnosis ("HCC/LT" group) and those treated with other modalities prior to antiviral therapy ("HCC" group).Of 17,487 HCV treatment recipients, 624 (3.6%) had prior HCC, including 142 with HCC/LT and 482 with HCC. Overall SVR was 91.9% in non- HCC, 74.5% in HCC, and 93.4% in HCC/LT. Among HCC patients, genotype 1 had the highest SVR overall (79.0% in HCC and 96.0% in HCC/LT), and genotype 3 the lowest (47.0% in HCC and 88.9% in HCC/LT). After adjustment for confounders, the presence of HCC was associated with lower likelihood of SVR overall (AOR 0.38 [95%CI 0.29, 0.48], p<.001).HCV can be cured with DAAs in the majority of patients with prior HCC, and in virtually all HCC patients post-liver transplant. Deferral of HCV treatment until the post-transplant setting may be considered among HCC patients listed for transplantation.Over three quarters of patients with hepatocellular carcinoma who have hepatitis C can achieve viral cure with direct acting antiviral drugs. Among patients with hepatocellular carcinoma who subsequently received liver transplantation, over 90% of patients can achieve viral cure. Pubmed

Leave a Reply

Your email address will not be published. Required fields are marked *